BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 21448141)

  • 1. Medical therapy in acromegaly.
    Sherlock M; Woods C; Sheppard MC
    Nat Rev Endocrinol; 2011 May; 7(5):291-300. PubMed ID: 21448141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acromegaly.
    Dineen R; Stewart PM; Sherlock M
    QJM; 2017 Jul; 110(7):411-420. PubMed ID: 26873451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current and future medical treatments for patients with acromegaly.
    Maffezzoni F; Formenti AM; Mazziotti G; Frara S; Giustina A
    Expert Opin Pharmacother; 2016 Aug; 17(12):1631-42. PubMed ID: 27352098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological management of acromegaly: a current perspective.
    Manjila S; Wu OC; Khan FR; Khan MM; Arafah BM; Selman WR
    Neurosurg Focus; 2010 Oct; 29(4):E14. PubMed ID: 20887124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical therapy in patients with acromegaly: predictors of response and comparison of efficacy of dopamine agonists and somatostatin analogues.
    Sherlock M; Fernandez-Rodriguez E; Alonso AA; Reulen RC; Ayuk J; Clayton RN; Holder G; Sheppard MC; Bates A; Stewart PM
    J Clin Endocrinol Metab; 2009 Apr; 94(4):1255-63. PubMed ID: 19158203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acromegaly.
    Scacchi M; Cavagnini F
    Pituitary; 2006; 9(4):297-303. PubMed ID: 17077948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy for the syndromes of GH excess.
    Arosio M; Cannavò S; Epaminonda P; Ronchi C; Chiodini I; Adda G
    J Endocrinol Invest; 2003; 26(10 Suppl):36-43. PubMed ID: 15497658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapeutic management of acromegaly].
    Metzner C; Hadziselimovic S; Grafe I; Nawroth P; Kasperk C
    Med Klin (Munich); 2006 Jan; 101(1):15-23. PubMed ID: 16418810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of acromegaly.
    Holdaway IM
    Horm Res; 2004; 62 Suppl 3():79-92. PubMed ID: 15539805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medical treatment in acromegaly.
    Paisley AN; Trainer PJ
    Curr Opin Pharmacol; 2003 Dec; 3(6):672-7. PubMed ID: 14644022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical therapy of acromegaly: efficacy and safety of somatostatin analogues.
    Feelders RA; Hofland LJ; van Aken MO; Neggers SJ; Lamberts SW; de Herder WW; van der Lely AJ
    Drugs; 2009 Nov; 69(16):2207-26. PubMed ID: 19852525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bromocriptine, a dopamine agonist, increases growth hormone secretion in a patient with acromegaly.
    Arihara Z; Sakurai K; Yamashita R; Niitsuma S; Ueno T; Yamamura N; Yamada S; Inoshita N; Takahashi K
    Tohoku J Exp Med; 2014 Oct; 234(2):129-35. PubMed ID: 25253414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pegvisomant: an advance in clinical efficacy in acromegaly.
    Stewart PM
    Eur J Endocrinol; 2003 Apr; 148 Suppl 2():S27-32. PubMed ID: 12670298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current therapy and drug pipeline for the treatment of patients with acromegaly.
    Kumar SS; Ayuk J; Murray RD
    Adv Ther; 2009 Apr; 26(4):383-403. PubMed ID: 19444656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acromegaly: a new therapy.
    Friend KE
    Cancer Control; 2002; 9(3):232-5. PubMed ID: 12090246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly.
    Colao A; Attanasio R; Pivonello R; Cappabianca P; Cavallo LM; Lasio G; Lodrini A; Lombardi G; Cozzi R
    J Clin Endocrinol Metab; 2006 Jan; 91(1):85-92. PubMed ID: 16263832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The place of pegvisomant in the acromegaly treatment algorithm.
    Paisley AN; Trainer PJ; Drake WM
    Growth Horm IGF Res; 2004 Jun; 14 Suppl A():S101-6. PubMed ID: 15135788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of endocrine disease: GH excess: diagnosis and medical therapy.
    Andersen M
    Eur J Endocrinol; 2014 Jan; 170(1):R31-41. PubMed ID: 24144967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological therapy for acromegaly: a critical review.
    Muller AF; Van Der Lely AJ
    Drugs; 2004; 64(16):1817-38. PubMed ID: 15301564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly.
    Jawiarczyk A; Kałuzny M; Bolanowski M; Bednarek-Tupikowska G
    Neuro Endocrinol Lett; 2008 Aug; 29(4):571-6. PubMed ID: 18766168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.